Bumetanide to Treat Parkinson Disease: A Report of 4 Cases.
Identifieur interne : 001915 ( Ncbi/Curation ); précédent : 001914; suivant : 001916Bumetanide to Treat Parkinson Disease: A Report of 4 Cases.
Auteurs : Philippe Damier [France] ; Constance Hammond ; Yeheskel Ben-AriSource :
- Clinical neuropharmacology [ 1537-162X ]
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Bumetanide, Sodium Potassium Chloride Symporter Inhibitors.
- drug therapy : Parkinson Disease.
- Aged, Female, Humans, Male, Middle Aged.
Abstract
Relying on recent experimental data in 2 animal models of Parkinson disease (PD), we have tested the effects of the loop diuretic bumetanide as an add-on treatment to dopaminergic drugs in 4 volunteered patients with PD using the Unified Parkinson's Disease Rating Scale. Bumetanide is a specific antagonist of the chloride importer NKCC1 (sodium/potassium/chloride cotransporter isoform 1) that ameliorates neuronal inhibition by reducing intracellular chloride levels in a variety of pathological conditions. Bumetanide is however not labeled for use in PD. We report an improvement of PD motor symptoms in the 4 patients treated with bumetanide (5 mg/d for 2 months). Bumetanide also improved gait and freezing in 2 of these patients. Our results suggest that bumetanide is well tolerated and call for double-blind, placebo-controlled, randomized trials to confirm the therapeutic efficacy of bumetanide.
DOI: 10.1097/WNF.0000000000000114
PubMed: 26757306
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000215
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :000214
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000214
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :001915
Links to Exploration step
pubmed:26757306Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Bumetanide to Treat Parkinson Disease: A Report of 4 Cases.</title>
<author><name sortKey="Damier, Philippe" sort="Damier, Philippe" uniqKey="Damier P" first="Philippe" last="Damier">Philippe Damier</name>
<affiliation wicri:level="3"><nlm:affiliation>*CHU Nantes, Nantes; and †INMED, INSERM U 901 and B&A Therapeutics, Campus Scientifique de Luminy, Marseille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>*CHU Nantes, Nantes; and †INMED, INSERM U 901 and B&A Therapeutics, Campus Scientifique de Luminy, Marseille</wicri:regionArea>
<placeName><region type="region">Provence-Alpes-Côte d'Azur</region>
<region type="old region">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hammond, Constance" sort="Hammond, Constance" uniqKey="Hammond C" first="Constance" last="Hammond">Constance Hammond</name>
</author>
<author><name sortKey="Ben Ari, Yeheskel" sort="Ben Ari, Yeheskel" uniqKey="Ben Ari Y" first="Yeheskel" last="Ben-Ari">Yeheskel Ben-Ari</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="????"><PubDate><MedlineDate>2016 Jan-Feb</MedlineDate>
</PubDate>
</date>
<idno type="RBID">pubmed:26757306</idno>
<idno type="pmid">26757306</idno>
<idno type="doi">10.1097/WNF.0000000000000114</idno>
<idno type="wicri:Area/PubMed/Corpus">000215</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000215</idno>
<idno type="wicri:Area/PubMed/Curation">000214</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000214</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000214</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000214</idno>
<idno type="wicri:Area/Ncbi/Merge">001915</idno>
<idno type="wicri:Area/Ncbi/Curation">001915</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Bumetanide to Treat Parkinson Disease: A Report of 4 Cases.</title>
<author><name sortKey="Damier, Philippe" sort="Damier, Philippe" uniqKey="Damier P" first="Philippe" last="Damier">Philippe Damier</name>
<affiliation wicri:level="3"><nlm:affiliation>*CHU Nantes, Nantes; and †INMED, INSERM U 901 and B&A Therapeutics, Campus Scientifique de Luminy, Marseille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>*CHU Nantes, Nantes; and †INMED, INSERM U 901 and B&A Therapeutics, Campus Scientifique de Luminy, Marseille</wicri:regionArea>
<placeName><region type="region">Provence-Alpes-Côte d'Azur</region>
<region type="old region">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hammond, Constance" sort="Hammond, Constance" uniqKey="Hammond C" first="Constance" last="Hammond">Constance Hammond</name>
</author>
<author><name sortKey="Ben Ari, Yeheskel" sort="Ben Ari, Yeheskel" uniqKey="Ben Ari Y" first="Yeheskel" last="Ben-Ari">Yeheskel Ben-Ari</name>
</author>
</analytic>
<series><title level="j">Clinical neuropharmacology</title>
<idno type="eISSN">1537-162X</idno>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Bumetanide (therapeutic use)</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Sodium Potassium Chloride Symporter Inhibitors (therapeutic use)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Bumetanide</term>
<term>Sodium Potassium Chloride Symporter Inhibitors</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Relying on recent experimental data in 2 animal models of Parkinson disease (PD), we have tested the effects of the loop diuretic bumetanide as an add-on treatment to dopaminergic drugs in 4 volunteered patients with PD using the Unified Parkinson's Disease Rating Scale. Bumetanide is a specific antagonist of the chloride importer NKCC1 (sodium/potassium/chloride cotransporter isoform 1) that ameliorates neuronal inhibition by reducing intracellular chloride levels in a variety of pathological conditions. Bumetanide is however not labeled for use in PD. We report an improvement of PD motor symptoms in the 4 patients treated with bumetanide (5 mg/d for 2 months). Bumetanide also improved gait and freezing in 2 of these patients. Our results suggest that bumetanide is well tolerated and call for double-blind, placebo-controlled, randomized trials to confirm the therapeutic efficacy of bumetanide.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001915 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 001915 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= Ncbi |étape= Curation |type= RBID |clé= pubmed:26757306 |texte= Bumetanide to Treat Parkinson Disease: A Report of 4 Cases. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:26757306" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \ | NlmPubMed2Wicri -a ParkinsonFranceV1
This area was generated with Dilib version V0.6.29. |